Agoracom: Small Cap Investment - Resverlogix Corp. - Re: Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy

...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy

Oct 04, 2023 08:44AM

Re: Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy

KOO-KOO2

Oct 04, 2023 09:03AM

Re: Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy

10BagR

Oct 04, 2023 10:05AM

Re: Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy

KOO-KOO2

Oct 04, 2023 11:41AM

Re: Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy

Toinv

Oct 04, 2023 01:25PM

Re: Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy

jonzobot

Oct 04, 2023 01:27PM

jbuffett62

Rank: Treasurer [?]

Points: 480 [?]

Votes: 13 Score: 2.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy

in response to

Re: Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy

jonzobot

posted on Oct 04, 2023 01:49PM

https://www.fda.gov/medical-devices/investigational-device-exemption-ide/expanded-access-medical-devices

2 Recommendations

Re: Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy